News

Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...
Mirage News6d
AACR: Olaparib-Pembrolizumab Combo Shows Early Promise
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...